Comunicati Stampa
Industria

SYENSQO - Second Quarter 2024 Results

SYENSQO SECOND QUARTER 2024 RESULTSBrussels, Belgium – August 1, 2024 - 7:00AM CEST CONTINUED IMPROVEMENT IN YEAR-ON-YEAR VOLUME MOMENTUM  UNDERLYING EBITDA OF €378 MILLION IN LINE WITH EXPECTATIONS, WITH STRONG CASH CONVERSION FULL YEAR 2024 OUTLOOK RANGE NARROWED Underlying (€ million)Q2 2024Q2 2023Q1 2024YoY changeYoY organicQoQ change H1 2024H1 2023YoY changeYoY organicNet sales1,7081,8151,624-5.9%-5...
Brussels, (informazione.it - comunicati stampa - industria)

SYENSQO SECOND QUARTER 2024 RESULTS

Brussels, Belgium – August 1, 2024 - 7:00AM CEST

CONTINUED IMPROVEMENT IN YEAR-ON-YEAR VOLUME MOMENTUM 
UNDERLYING EBITDA OF €378 MILLION IN LINE WITH EXPECTATIONS, WITH STRONG CASH CONVERSION
FULL YEAR 2024 OUTLOOK RANGE NARROWED

Highlights

Dr. Ilham Kadri, CEO

“We delivered on our outlook for the second quarter, thanks in particular to improved year-on-year volume momentum, most notably in Novecare, as well as discipline on pricing and control of our costs. We also saw another quarter of double digit growth in Composite Materials and continued to generate robust cash flow.

While we expect to return to year-on-year volume growth in the second half of 2024, we see a slower recovery in certain end markets, as well as ongoing macroeconomic uncertainty. Nevertheless, we remain relentlessly focused on what is within our control, bringing solutions that our customers need, tightly managing our costs and capital expenditure to further improve our operating leverage and returns, which will allow Syensqo to deliver growth and value creation as markets improve.

2024 Outlook 

While our second quarter 2024 results benefited from improved volume momentum, we do not expect a broader recovery in overall demand in the second half of the year that would support the higher end of our previous outlook ranges. 

More specifically, we now expect a slower recovery in a number of end markets impacted by ongoing macroeconomic uncertainty, most notably Automotive, Agro, Industrial and Medical while we expect continued strong growth in the Aerospace and Defence markets.

For the second half of 2024, we expect to return to year-on-year volume growth, driven by higher volumes in all business units, particularly in Novecare.

As a result, our full year 2024 outlook is now as follows:

Safe harbor

This press release may contain forward-looking information. Forward-looking statements describe expectations, plans, strategies, goals, future events or intentions. The achievement of forward-looking statements contained in this press release is subject to risks and uncertainties relating to a number of factors, including general economic factors, interest rate and foreign currency exchange rate fluctuations, changing market conditions, product competition, the nature of product development, impact of acquisitions and divestitures, restructurings, products withdrawals, regulatory approval processes, all-in scenario of R&I projects and other unusual items. Consequently, actual results or future events may differ materially from those expressed or implied by such forward-looking statements. Should known or unknown risks or uncertainties materialize, or should our assumptions prove inaccurate, actual results could vary materially from those anticipated. The Company undertakes no obligation to publicly update or revise any forward-looking statements.

About Syensqo 

Syensqo is a science company developing groundbreaking solutions that enhance the way we live, work, travel and play. Inspired by the scientific councils which Ernest Solvay initiated in 1911, we bring great minds together to push the limits of science and innovation for the benefit of our customers, with a diverse, global team of more than 13,000 associates. 
Our solutions contribute to safer, cleaner, and more sustainable products found in homes, food and consumer goods, planes, cars, batteries, smart devices and health care applications. Our innovation power enables us to deliver on the ambition of a circular economy and explore breakthrough technologies that advance humanity.

Investor Relations Resources

Contacts

Attachments


Ufficio Stampa
 Nasdaq GlobeNewswire (Leggi tutti i comunicati)
2321 Rosecrans Avenue. Suite 2200
90245 El Segundo Stati Uniti
Allegati
Non disponibili